In conclusion, this study proposes that the genetic or pharmacological inhibition of IRP2 in BC cells may serve as a novel therapeutic strategy for increasing radiosensitivity and overcoming resistance by inducing mitochondrial dysfunction. The gene discussed is IREB2; the disease is breast cancer.